logo
logo

Bgf, Scottish National Investment Bank And Scottish Enterprise To Invest £8M Elasmogen

May 18, 2022•about 3 years ago

Amount Raised

£8 Million

Aberdeen

Description

Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its soloMERTM platform – has secured £8 million investment.

Company Information

Company

Elasmogen

Location

Aberdeen, Washington, United States

About

The funding round was led by BGF and Scottish National Investment Bank (The Bank), with additional support from existing investor Scottish Enterprise. The multi-million-pound investment will enable Aberdeen-based Elasmogen to continue developing its pipeline of next-generation drugs through pre-clinical trials. The company’s soloMERTM technology is based on molecules naturally found in sharks’ immune systems, which are the equivalent of human antibodies but smaller and more stable.